Full-Time

Automation Support Engineer

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Compensation Overview

$95.5k - $119.4k/yr

Junior, Mid

Company Historically Provides H1B Sponsorship

Austin, TX, USA

Category
Lab & Research
Life Sciences
Requirements
  • BS degree in Biomedical engineering, closely related scientific field, or equivalent; MS degree preferred
  • 2+ years of laboratory automation engineering experience required
  • Technical proficiency and experience in automation and systems development and integration for the life science industry; especially with robotics and liquid handling systems
  • Experience in computer programming is required
Responsibilities
  • Support liquid handling robots.
  • Build knowledge on hardware and software on multiple types of laboratory automated liquid handlers, such as Tecan Fluent, Hamilton STAR and Vantage, and Beckman i7, among others
  • Build rapport with end-users, and coordinate with cross-functional teams
  • Prepare documentation for equipment qualification and operating procedures to ensure successful implementation in the labs
  • Prepare User Requirement and Testing Procedure, Standard Operating Procedures, and related documentations
  • Oversee the functional and validation testing, IQ/OQ/PQ
  • Additional responsibilities include user training, troubleshooting, and on-going support for the end-users
Desired Qualifications
  • Biotech, pharmaceutical, Lab automation providers, or clinical-laboratory experience is highly desirable

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through precise genetic insights.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Natera's expansion in Austin indicates growth and increased operational capacity by 2026.
  • The launch of the ultra-sensitive Signatera MRD test broadens Natera's clinical offerings.
  • Rising demand for personalized medicine aligns with Natera's mission and service offerings.

What critics are saying

  • Increased competition from companies like Lantheus Holdings may impact market share.
  • Significant capital investments, like the $9.9 million Austin expansion, may affect cash flow.
  • Dependence on insurance reimbursements poses financial risks if policies change.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for oncology, organ health, and women's health.
  • The company offers the Signatera test, a custom-built ctDNA test for cancer patients.
  • Natera provides remote genetic counseling services, enhancing accessibility for patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

5%
Intelligence360
May 15th, 2025
Natera To Spend $9.9 Million To Occupy 30,000 Square Feet Of Space In Austin Texas.

Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas. Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas.Austin, Texas — According to state and local development sources, Natera plans to invest $9,900,000.00 to build out 30,000 square feet of new space in Austin. The company plans to occupy the new space at 13011A McCallen Pass in Austin, on or about January 1, 2026. According to the company website Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, womens health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment

TXBN
Apr 24th, 2025
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera(TM) Genome MRD Test

Natera announces broad clinical launch of ultra-sensitive signatera(tm) genome MRD test.

Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).

TXBN
Mar 25th, 2025
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.

Simply Wall St
Mar 13th, 2025
Natera (NasdaqGS:NTRA) Welcomes Former National Cancer Institute Director Back to Board

Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.